AWS becomes Novo Nordisk's preferred cloud provider for drug discovery, opens London AI hub

The deal deepens AWS's push into life sciences, pairing Novo Nordisk's scientific expertise with AWS's AI and compute stack. The dedicated London co-innovation hub focuses on connecting genomic, imaging and clinical data across the discovery process using Amazon Bio Discovery and Amazon Bedrock, enabling what AWS's Matt Wood described as tighter cycles of hypothesis, computation, experimentation and learning.

Mechanically, the collaboration puts frontier AI tooling against one of pharma's hardest bottlenecks: the time and cost from identifying a drug target to reaching first human dose. By unifying scattered data types and applying generative and predictive models, the partners aim to accelerate hypothesis generation and candidate screening.

Amazon CEO Andy Jassy and Chief AI & Technology Officer Matt Wood both amplified the announcement, signaling its strategic weight. It positions AWS against Google (via Isomorphic Labs and DeepMind's AlphaFold lineage) and Microsoft in the increasingly competitive AI-for-biology arena.

Competitively, the win matters because pharma is a marquee vertical where cloud providers compete on domain-specific tooling, not just raw compute. Skeptics will note that drug-discovery partnerships are long-horizon bets whose payoff is measured in years and clinical outcomes, not quarters. What to watch: concrete milestones from the London hub and whether AWS can convert this flagship into broader pharma adoption.